Skip to main content
SCPX
OTC Life Sciences

Scorpius Holdings Disposes of Substantially All Assets via Foreclosure, Becomes Shell Company

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
10
Price
$0
Mkt Cap
$18.343K
52W Low
$0
52W High
$0.8
Market data snapshot near publication time

summarizeSummary

Scorpius Holdings, Inc. formally disclosed the December 10, 2025 foreclosure sale of substantially all its non-cash assets, confirming its status as a shell company and partial settlement of significant secured debt.


check_boxKey Events

  • Foreclosure Sale Completed

    Substantially all non-cash assets, including CDMO and R&D operations, were foreclosed upon on December 10, 2025, by a collateral agent on behalf of secured noteholders.

  • Debt Partially Settled

    $15.2 million in net proceeds from the sale were used to partially settle $30.2 million in secured debt, leaving a substantial balance of approximately $15 million.

  • Shell Company Status Confirmed

    The disposition of assets confirms the company's transition to a 'shell company,' as previously indicated in the January 12, 2026 10-Q filing.

  • Workforce Terminated

    All CDMO employees were terminated on December 10, 2025, with a majority joining the buyer, Velocity Bioworks, Inc.


auto_awesomeAnalysis

This 8-K provides the formal and detailed disclosure of the foreclosure event that led to Scorpius Holdings, Inc. becoming a shell company, as previously indicated in the January 12, 2026 10-Q filing. The company lost substantially all its operating assets, including its CDMO and R&D activities, due to a foreclosure sale by secured noteholders on December 10, 2025. While $15.2 million in net proceeds from the sale were used to partially settle $30.2 million in secured debt, a significant amount of secured debt remains. This event fundamentally alters the company's business model and future prospects, confirming its effective cessation as an operating entity. Investors should be aware of the severe implications for the company's viability.

At the time of this filing, SCPX was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $18.3K. The 52-week trading range was $0.00 to $0.80. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed SCPX - Latest Insights

SCPX
Apr 07, 2026, 5:43 PM EDT
Filing Type: 8-K
Importance Score:
8
SCPX
Mar 19, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
SCPX
Mar 10, 2026, 4:15 PM EDT
Filing Type: 8-K/A
Importance Score:
9
SCPX
Feb 17, 2026, 4:35 PM EST
Filing Type: 10-Q
Importance Score:
10
SCPX
Jan 29, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
10
SCPX
Jan 13, 2026, 4:57 PM EST
Filing Type: 8-K
Importance Score:
9
SCPX
Jan 12, 2026, 4:31 PM EST
Filing Type: 10-Q
Importance Score:
10